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Abstract
Sex differences are well known to be determinants of development, health and disease. Epigenetic mechanisms are also
known to differ between men and women through X-inactivation in females. We hypothesized that epigenetic sex
differences may also result from sex hormone functions, in particular from long-lasting androgen programming. We aimed
at investigating whether inactivation of the androgen receptor, the key regulator of normal male sex development, is
associated with differences of the patterns of DNA methylation marks in genital tissues. To this end, we performed large
scale array-based analysis of gene methylation profiles on genomic DNA from labioscrotal skin fibroblasts of 8 males and 26
individuals with androgen insensitivity syndrome (AIS) due to inactivating androgen receptor gene mutations. By this
approach we identified differential methylation of 167 CpG loci representing 162 unique human genes. These were
significantly enriched for androgen target genes and low CpG content promoter genes. Additional 75 genes showed a
significant increase of heterogeneity of methylation in AIS compared to a high homogeneity in normal male controls. Our
data show that normal and aberrant androgen receptor function is associated with distinct patterns of DNA-methylation
marks in genital tissues. These findings support the concept that transcription factor binding to the DNA has an impact on
the shape of the DNA methylome. These data which derived from a rare human model suggest that androgen
programming of methylation marks contributes to sexual dimorphism in the human which might have considerable impact
on the manifestation of sex-associated phenotypes and diseases.
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Introduction
A wealth of phenotypic dimorphisms differentiates males from
females. While the most evident sexual dimorphism occurs in the
genitalia, there are also many extra-genital sites of the body
characterized by sexual dimorphisms of anatomy and function
including sex specific differentiation of the brain [1]. Eventually,
behavioral traits have a well-documented sex specificity already
present in children [2,3]. Various human diseases show sex-
specific incidences, e.g., cancers like mantle cell lymphoma [4] and
Burkitt lymphoma [5] as well as auto-immune diseases like
Sjo¨gren’s Syndrome [6] and systemic lupus erythematodes [7].
Biological sex also modifies risks for common disorders like asthma
[8] and cardiovascular disease [9]. This indicates that sexual
dimorphism is an important human phenotype modifier that can
affect prevalence, course and severity of diseases [10].
Male or female biological sex is only initially determined by the
presence or the absence of the SRY-gene on the Y-chromosome
resulting in either testicular or ovarian development (i.e. gonadal
sex). It is indeed the presence or absence of androgen (testosterone
and dihydrotestosterone, respectively) activating the androgen
receptor (AR) pathway between the 8th to 13th week of gestation
which is the key determinant for establishing the male or the
female phenotypic sex [11]. It is, however, still largely unknown,
how androgens and the AR pathway implement human sexual
dimorphisms.
At the cellular level, activation of the AR by androgen results in
tissue-specific up – and down-regulation of gene transcription in
androgen responsive tissues, e.g., in genital skin fibroblasts [12] or
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in the prostate [13]. In addition to this classical endocrine
perspective of AR function a set of elegant experiments in rats has
previously indicated a male androgen programming window in
which the early prenatal androgen environment determines key
features of the adult sexual phenotype like phallus size, anogenital
distance and Sertoli-cell number. This program can only in part be
modified by postnatal androgen supply [14,15]. Interestingly,
there is also increasing evidence from other animal studies showing
that prenatal androgen programming may be an important
modifier of extragenital health states and diseases, e.g., via CNS-
programming of weight control [16,17] or via androgen
programming of liver function and insulin sensitivity [18–20].
Anway and coworkers have induced early prenatal disruption of
the AR pathway in rat embryos by intraperitoneal injections of the
anti-androgen vinclocolin in mother rats [21–24]. The authors
have shown that this treatment has been associated with
comprehensive changes of the embryonic F1 testis transcriptome
including the DNA methyltransferase genes Dnmt3A and
Dnmt3L. In addition, transcriptional changes also occurred in
F2 - F3 generation animals indicating transgenerational epigenetic
effects of this drug [24]. Moreover, adult F1 animals and
subsequent generations F2 - F4 developed various disease states
and tissue abnormalities including prostate disease, kidney disease,
immune system abnormalities, reduced spermatogenic capacity
and tumor development [22,23]. These findings suggest long
lasting and transgenerational impact of the embryonic AR
pathway disruption. Intriguingly, comparable transgenerational
changes of gene transcription in response to vinclocolin have been
observed in the rat brain transcriptome being accompanied by
behavioral changes in respective animals [25].
In contrast to animals it is much more difficult to prove
androgen programming in humans since experimental hormonal
interventions are not possible for ethical reasons. Moreover, since
males and females always differ simultaneously in both, sex
chromosomes and sex hormones, it is hardly possible to decipher
their differential influences on sexual dimorphisms. Remarkably,
unique natural human models to distinguish chromosomal and
hormonal influences are disorders of sex development (DSD), in
particular the androgen insensitivity syndrome (AIS) in which
inactivating mutations in the AR-gene abolish the AR-signaling
pathway. This leads to impaired masculinization in genetically
male individuals carrying a 46,XY karyotype. AIS-phenotypes
range from complete AIS (CAIS) with normal female external
genitalia through partially virilized (ambiguous) genitalia (PAIS) to
minimal AIS (MAIS) with only infertility in otherwise normal
males depending on the residual AR function [26]. Using AIS as a
model, we showed previously by microarray analyses at the
transcriptome level that androgens were able to program long-
term persisting gene transcription patterns in human tissues, e.g.,
in external genital fibroblasts [27,28] as well as even outside the
genitalia in peripheral blood mononuclear cells [29].
We here hypothesized that androgen programming in the
human occurs at the epigenome level, especially by differential
programming of DNA-methylation states. While there is increas-
ing evidence for the role of epigenetics in tissue differentiation and
disease modification [30,31], the potential role of epigenetics in
shaping sexual dimorphisms and particularly the involvement of
sex hormones therein are hardly understood. Up to date, X-
inactivation is the major example of sex-specific epigenetic
differences between males and females in humans but it depends
on the number of X-chromosomes rather than presence or
absence of sex hormones, namely androgens [32,33]. We here
show by microarray based methylation profiling that 46,XY
individuals with an AR pathway disruption due to inactivating AR
mutations have significant changes of their epigenomic signature
in genital fibroblasts compared with normal males and intact AR.
Therefore, our experiments suggest that androgen programming
in the human results in changes in the epigenome.
Methods
Cell Culture
The study was approved by the ethical committee of the
Christian-Albrechts-University of Kiel (CAU), Germany (D410/
08). For samples included in the study which were obtained in the
framework of the Euro DSD project (FP7 project 201444 from
2008 to 2011) written informed consent has been obtained in
accordance with the protocols approved by the ethical commitee
of the Christian Albrechts-University of Kiel (AZ: D410/08;
http://www.eurodsd.eu/en/ethics.php). For fibroblast cultures
established before Euro DSD, verbal informed consent was
obtained by the surgeons operating the patient and taking the
biopsy according to ethical approval and in line with respective
institutional guidelines. A form documenting information and
consent in the patients’ clinical files was provided according to
ethical approval. Cell culture of 46,XY primary fibroblasts from
scrotum/labia majora from donors with PAIS (n = 13), MAIS
(n = 1) or CAIS (n = 12) and 8 male controls as well as isolation of
genomic DNA were performed as detailed in [4]. The definition
‘‘control’’ in this study is based on the clinical documentation of a
completely normal male external genital phenotype (i.e., complete
androgen-mediated fusion of the male genital midline) as opposed
to the incomplete or absent external genital virilization in the PAIS
and the CAIS patients, respectively. The one MAIS patient had
originally been assigned to the normal controls due to a normal
male phenotype of the external genitalia (‘‘S8’’). However, our
previous functional characterization of this fibroblast strain had
revealed impaired androgen-mediated induction of the AR target
gene APOD [12]. Subsequent sequence analysis of the AR gene
showed that this person indeed carried a p.I841S AR gene
mutation [12] and thus suffered from a mild form of AIS (MAIS)
with the clinical symptom of isolated male infertility. Therefore,
this sample was allocated as AIS sample despite normal male
external virilization for analyses in this study. Mutational analyses
in the remaining normal male controls (S3, S4, S5, S9, S11, S12,
S13, S15) did not reveal AR gene mutations. Complete data are
available at Gene Expression Omnibus (GSE31362).
DNA Methylation Analysis
DNA methylation analysis using HumanMethylation27 Bead-
Chips was performed as described [34,35]. 13 AIS samples and all
controls were analyzed in duplicates. Samples with gene call rates
,95% as analyzed with BeadStudio software (Illumina, Inc.) and
CpGs with detection p-values .0.05 in at least one experiment
were excluded from analyses. 54 hybridizations with 25,988 CpGs
entered the analysis.
Hierarchical cluster analyses based on average beta-values were
performed using OMICS Explorer (v.2.1(25); Qlucore, Sweden).
Reproducibility and accuracy of results obtained with the
HumanMethylation27 BeadChip have been shown by us and
others before [35]. Single nucleotide polymorphisms putatively
interfering with DNA methylation analysis were identified using
information provided by Illumina (https://my.illumina.com/
myillumina/bulletin/K0igwwHjyE-5J35-sPKU2A/using-
humanmethylation450-and-understanding-underl). Polymor-
phisms with an allele frequency .5% in the population which
are located within a distance of 3 bp next to the cytosine analyzed
Sexual Dimorphism Is Linked to DNA Methylation
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on the array were identified (Tables S2 and S3 (‘‘SNP’’)). The
Venny software package was used to generate venn diagrams [36].
Analysis of Enrichment for Promoter Classes in
Differentially Methylated Genes, Imprinted Genes and AR
Target Genes
Proportions of imprinted genes, AR target genes and promoter
classes in the particular groups of genes and the genes present on
the HumanMethylation27 Bead Chip were compared using the x2
test (two-sided; Prism, ver. 4.02). Relative risks and odds ratios
were calculated using Prism.
Information on imprinted genes was taken from Luedi et al.
[37] as well as on freely accessible databases (http://igc.otago.ac.
nz and http://www.geneimprint.com).
We used a previously suggested classification into promoters
with high (HCP), and low (LCP) CpG content promoter regions to
determine whether differentially methylated genes are character-
ized by different CpG compositions [38]. Information whether
CpG loci present on the array were located in a CpG island was
available from Illumina. For enrichment analysis of putative AR-
target genes in the group of differentially methylated genes as well
as of the genes present on the array GATHER has been utilized
(http://gather.genome.duke.edu [39]).
Analysis of Variability in the DNA Methylation Pattern
Here we focused on CpG with high variability in the AIS
samples but low variability in the controls. Therefore, CpGs
characterized by differences in their beta-values ranging in control
samples up to 0.34 and differences of the interquartile differences
above 0.16 between controls and AIS samples were considered as
being variably methylated in AIS. A deduction of these parameters
is detailed in the supplement (Methods S1). Applying an analogous
approach we determined loci showing high variability in normal
controls but not in AIS samples.
Results
Identification of DNA Methylation Patterns in Genital Skin
Fibroblasts of AIS Individuals
To provide insights on how androgen signaling may epigenet-
ically imprint human external genitalia derived cells independent
of the sex chromosomal composition, we have quantified the
DNA-methylation levels of 27,568 CpGs in cultured human skin
fibroblasts from the labioscrotal folds of individuals with molecular
proven AIS and different degrees of impaired external genital
virilization (n = 26) using an array based assay. Fibroblasts were
obtained from 12 CAIS individuals, 13 PAIS individuals, one
MAIS individual and 8 males with phenotypic normal male
Figure 1. Array-based DNA methylation analysis of 26 AIS genital fibroblasts and 8 male control genital fibroblasts. (A) Supervised
cluster analysis of DNA-methylation data obtained from genital fibroblasts separates individuals with AIS (yellow) from male controls (blue) (q,0.04).
DNA-methylation is presented on a relative scale. To demonstrate reproducibility all hybridizations performed in duplicates are shown separately. (B)
DNA-methylation of APOD (cg05624196) in fibroblasts lacking induction of APOD upon androgen treatment (non-responder) was significantly higher
compared to responding fibroblasts (responder). (C) Variability in the DNA-methylation in AIS (yellow) compared to male controls (blue). Green: low,
black: medium, red: high avg-beta values. The right bar indicates p-value (F-test).
doi:10.1371/journal.pone.0073288.g001
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external genitalia. Molecular analysis of the AR gene revealed
protein changing mutations in 24 AIS individuals. In two
individuals with AIS but no detectable protein changing mutations
biochemical analyses indicated impaired AR function (for details
see supplementary Table S1) [12,27]. Methylation values were
compared to those of males with phenotypic normal male external
genitalia. 25,988 CpG loci passed the quality tests. Duplicate
samples showed good concordance (r2-range 0.9874–0.9964).
To identify CpG loci differentially methylated between AIS
samples and controls we performed a differential methylation
analysis (Figure 1a, FDR,0.04, t-test). By this approach, a total of
167 CpG loci representing 162 unique human genes showed
significantly differential methylation in AIS as compared to the
controls. Of these, 36 genes (22%) were hypermethylated in AIS
samples while the majority of 126 genes (78%) were hypomethy-
lated in AIS samples. These data showed that the absence of intact
AR-signaling in genital fibroblasts of XY individuals with AIS is
associated with significant changes of DNA methylation.
Genes Aberrantly Methylated in AIS are Characterized by
Low CpG Content Promoters
To further characterize the aberrantly methylated genes in AIS
we have first classified the genes according to their promoter CpG
content into high CpG (HCP) and low CpG (LCP) promoter genes
(34). The genes found hypomethylated in AIS as compared to
controls were significantly enriched for genes characterized by low
CpG content promoters (LCP, p,0.0001, OR = 2.78, RR = 1.98)
while they were depleted for genes with high CpG content
promoters (HCP, p,0.0001, OR = 0.37, RR = 0.56, Figure 2).
Interestingly, genes found hypermethylated in AIS as compared to
controls were also enriched for genes with low CpG content
promoters (LCP, p,0.05, OR = 2.41, RR = 1.82). These results
suggest that genes with low CpG content promoters become
preferentially aberrantly methylated in AIS as compared to
controls.
Genes Hypomethylated in AIS are Enriched for Genes
Regulated by Genomic Imprinting
Moreover, to determine the impact of paternal imprinting, we
identified known imprinted genes [37] in the group of aberrantly
methylated genes in AIS. The genes found hypomethylated in AIS
were significantly enriched for genes regulated by genomic
imprinting (p = 0.0006, OR = 3.463, Figure 2). The imprinted
genes included GNAS, MEST, PEG3.
AR Target Genes are Aberrantly Methylated in AIS
We wondered whether due to the decreased AR activity, genes
regulated by AR were particularly susceptible to aberrant DNA
methylation in AIS as compared to the controls. Remarkably, the
genes hypermethylated in AIS were significantly enriched for AR
target genes identified by the GATHER tool [39] (p,0.0001,
OR = 5.23, RR = 4.06) (Figure 2, Table S2, Figure S1) while
hypomethylated genes were not enriched for AR targets
(OR = 1.17, RR = 1.16). These findings support the idea that lack
of AR binding to these genes due to AR mutations leads to the
establishment of aberrant DNA methylation patterns in AIS.
Low APOD Expression Inversely Correlates with DNA
Methylation
Among the genes hypermethylated in AIS samples was APOD
(Apolipoprotein D), which we have previously found to be strongly
androgen-inducible in scrotal fibroblasts [12]. Interestingly, those
AIS fibroblast strains that showed a significantly higher APOD
methylation level at the transcription start (TSS)
(chr3:196,792,172; NCBI36/hg18, TSS10) as compared to male
controls in our present study lacked androgen mediated APOD
induction in a previous study [12] (Figure 1C). Since DNA
methylation at the TSS correlates closely with gene repression [40]
and furthermore this CpG is located within a known DNase I
hypersensitive site [41], this might point to functional relevance of
Figure 2. Enrichment of genes either hypo- or hypermethylated in AIS as compared to normal controls. The bar plots show percentage
of loci either located in imprinted genes, genes containing either promoters with high CpG (HCP) or low CpG (LCP) content as well as the percentage
of AR target genes as determined by the GATHER tool. Grey bars: percentage of genes present on the array, black bars: percentage of genes
hypomethylated and white bars: percentage of genes hypermethylated in AIS patients. p-values have been determined applying x2-test.
doi:10.1371/journal.pone.0073288.g002
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the methylation status for transcriptional control of APOD (Figure
S2).
Disruption of the AR Pathway in AIS Significantly
Increases the Variability of DNA Methylation in a Set of
Genes in Genital Skin Fibroblasts
By analyzing the DNA methylation data we noted a striking
variability in the DNA methylation of numerous CpG loci in the
AIS patients which was not observed in the normal male controls
with intact AR. Consequently, we focused our analyses on
systematic identification of the CpG loci with high variability in
AIS samples and low variability in control samples and vice versa.
In essence, we detected 79 CpG loci (corresponding to 75 genes;
Table S3) with variable DNA-methylation in AIS, but homoge-
nous DNA-methylation in controls. Vice versa, there was only a
small set of genes (n = 3) with high variability of methylation in
male controls, but homogeneous methylation in AIS (Figure 1C)
(p,0.001). Thus, the number of genes with variable methylation
was significantly higher in AIS than in controls. Remarkably, the
list of genes differentially methylated between AIS and controls as
identified by our first approach (see above) and the list of genes
characterized by a high variability in DNA methylation in AIS
overlapped in only 4 CpG loci (Figure S3). Interestingly, like the
hypomethylated genes described above, the genes with variable
DNA methylation in AIS were significantly enriched for genes
with LCP (p,0.001, OR = 2.38, RR = 1.81) and depleted for
genes with HCP (p,0.0001, OR = 0.37, RR = 0.56). There was
no enrichment of known imprinted genes (n = 2) and, in particular,
no enrichment of AR target genes (n = 0). To address the question
whether genetic polymorphisms (SNPs) mimicked epigenetic
variability causing misleading results, we identified CpG loci with
a frequency .5% in the population which are located within a
distance of 3 bp next to the cytosine analyzed on the array. Only
2 CpG loci (cg08008233 and cg12215675) fulfilled these criteria
(Table S3). Thus, genetic variability can most likely be excluded as
a major reason for the epigenetic variability found in AIS patients.
Discussion
We here show that mutational disruption of one single nuclear
hormone receptor pathway, the AR pathway in humans, leads to
significant alterations of DNA methylation of numerous genes in
cultured genital fibroblasts of 46,XY individuals with AIS
compared with comparable cells from normal 46,XY males
having an intact AR. Therefore, our data support the idea that
androgens epigenetically program sexual dimorphism in the
human by changing DNA methylation marks in the epigenome.
Our data are well in accordance with our previous studies
demonstrating long-term androgen programming of the tran-
scriptomes in these cells [27,28] and outside the genitalia in
peripheral blood mononuclear cells [29].
Intriguingly, the methylation changes in AIS occur in two
qualitatively distinct patterns comprising two different sets of genes
with only 6 genes contributing to both groups. The first and most
obvious pattern involves 162 genes differentially methylated
between AIS and normal controls. The second pattern involves
75 genes and it is characterized by an overt and statistically
significant increase of variability of DNA methylation in AIS
which is not observed in male control cells with an intact AR.
One of the most striking observations when analyzing the gene
set of the first pattern is that there is a significant enrichment of
AR target genes among the genes hypermethylated in AIS. This
observation might be explained by a current model suggesting that
diminished gene activation (e.g. due to mutations in activating
receptors) results subsequently in increased DNA methylation of
the silenced genes [42–44]. This is supported by our functional
analyses showing, that those AIS fibroblast strains that lacked
androgen mediated APOD induction in a previous study [12]
showed a significantly higher APOD promoter methylation level as
compared to male controls in our present study.
Indeed, the APOD promoter contains a steroid hormone
response element [45–47] and we have previously shown that
APOD-mRNA is strongly androgen-inducible in normal male
scrotum fibroblasts with intact AR but not in 46,XY CAIS - and
PAIS labioscrotal fibroblasts [12]. Therefore, one might speculate
that the diminished AR activation of APOD finally leads to its
methylation in AIS. Figure 3 suggests a putative model how a
defective AR pathway might finally result into an aberrantly
shaped DNA methylome. Besides APOD, several additional AR
target genes have been found to be aberrantly methylated in AIS
as compared to male control cells (Table S2).
Figure 3. Model of establishment of DNA methylation patterns by AR activity. (A) Unmutated inactive androgen receptor (AR) binds
testosterone (T) activating the receptor. Activated AR binds directly (large arrow) to AR response elements on the DNA inducing gene expression
which subsequently prevents DNA methylation (‘‘gene1’’). Additionally either the activated AR itself or AR induced genes act on suppressor
complexes (S; dotted arrow) which repress particular sets of genes (‘‘gene2’’) leading finally to DNA methylation of silenced genes. (B) In AIS missing
AR activity prevents activation of AR target genes which might subsequently result to (stochastic de novo) DNA methylation of affected genes. In
contrast, genes usually silenced by AR (directly or by additional AR-dependent pathways) become expressed preventing DNA methylation. white
lollipops: unmethylated DNA, filled lollipops: methylated DNA.
doi:10.1371/journal.pone.0073288.g003
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Moreover, the group of genes differentially methylated in AIS
was enriched for low CpG content promoter genes. Such genes
have also been found enriched in other non-malignant diseases
[34]. In contrast, an enrichment of PRC2 target genes in
embryonic stem cells which has been reported for several tumor
entities [35,48] has not been found in this study (data not shown).
Additionally we detected a statistically significant increase of
stochastic variability of DNA methylation in a defined group of
genes in AIS. This variability was significantly pronounced in the
AIS patients as compared to male controls. Interestingly, in a
current report Stadler et al. described that in a mouse model the
interaction of transcription factors with the DNA is not only
sufficient but moreover necessary to establish a distinct DNA
methylation pattern [42], thus finally shaping the methylome at
regulatory regions. This is in line with our findings suggesting that
aberrant AR activity affects the DNA methylome. In AIS altered
AR binding might directly affect the DNA methylation status of
AR response elements (ARE). To a current model, DNA binding
of transcription factors is required to etablish a regular DNA
methylation pattern [42]. Besides a direct interruption of AR-
binding, altered AR activity might interfere via signaling cascades
also with the activity of genes and the load of proteins to regulatory
sequences not containing AREs. One might speculate that in these
cases protein binding to these DNA sequences is less efficient and
sometimes might finally result into a disturbed DNA methylation
pattern. We hypothesize that this mechanism could randomly
modify the transcriptional background in target tissues. Accord-
ingly, it may have roles in the variability and often unpredictability
of the individual phenotype occurring in many monogenic
diseases, particularly in AIS [49]. In this concept, the AR defect
itself would always play the overriding functional role as a gate
keeper. In case of complete inactivation of the AR, e.g., due to
disruptive mutations in the AR – gene like a direct stop codon, the
phenotype is invariably CAIS no matter of heterogeneity of gene
methylation. This is confirmed by the CAIS patients in our study
(e.g., ARD682, ARD1144, Table 1) in whom we have detected
random methylation patterns but who have always normal female
external genitalia. However, in partial AIS with preserved partial
function of AR signaling (e.g., ARD527 [49]), a random
methylation pattern may contribute to random transcriptional
modifications giving rise to phenotypic heterogeneity. In contrast,
a full functioning AR pathway in normal males will block random
methylation supporting full male external genital differentiation. It
is of interest in this respect, that many of the genes in the
variability list – despite the fact that this list is not significantly
enriched for AR targets - have documented roles in androgen2/
genital tissue-related biology. These genes include (I) genes linked
to spermatogenesis with e.g. CAMK4 encoding calcium/calmod-
ulin-dependent protein kinase IV [50] or CA2 encoding carbonic
anhydrase II [51] (II) genes associated with hypospadias like IRF6
encoding interferon regulatory factor 6 [52] or (III) genes involved
in prostate biology like MGMT encoding O-6-methylguanine-
DNA methyltransferase [53] or TMEPAI encoding transmem-
brane prostate androgen-induced RNA [54]. In addition, this list
includes genes associated with androgen function, including genes
linked to androgen receptor co-regulators like AATF (Apoptosis-
antagonising transcription factor) [55] or CDC2L2 (cell division
control like 2, CDK11-p58) [56], to androgen targets like
ALDH1A3 (aldehyde dehydrogenase 1A3) [57], CA2, FMO2
(Flavin-containing monooxygenase) [58] or TEMEPAI, and
eventually androgen programming (HOXA5) [59].
In summary, our data on a rare but exemplary human
monogenic disorder of sex development suggest that abnormal
AR-signaling in 46,XY individuals with AIS leads to significant
changes in DNA methylation including a subset of genes with
significantly increased heterogeneity of DNA methylation. In
contrast, normal AR-signaling imprints a homogenous DNA-
methylation, at least in genital fibroblasts. The observed methyl-
ation patterns are likely to be implemented prenatally when
phenotypic genital sex is established. Our observations give rise to
the concept that AR-mediated programming of methylation marks
may play a relevant role in the establishment and maintenance of
sexual dimorphisms in the human. In conclusion, androgen
programming of the epigenome may be of general importance for
the functional and phenotypic differences between males and
females in health and disease.
Supporting Information
Figure S1 Unsupervised hierarchical cluster analysis
and PCA of AIS samples and controls. (A) Unsupervised
hierarchical cluster analysis and (B) PCA of AIS samples (green
bars/spheres) and controls (red bars/spheres). Only CpG loci
annotated to AR target genes were included. A variance filter (s/
smax.0.1) was applied; normalization: mean = 0, variance = 1.
blue: low DNA methylation, yellow: high DNA methylation.
(TIF)
Figure S2 Overview of the transcription start site of
APOD as presented in the UCSC genome browser. The
position of the CpG locus hypermethylated in AIS is indicated.
Furthermore, DNaseI hypersensitive sites and transcription factor
binding sites identified by the ENCODE project are shown.
(TIF)
Figure S3 Venn diagram of CpG loci characterized by
hypermethylation, hypomethylation or high variability.
Venn diagram of CpG loci hypermethylated (‘‘hypo’’, n = 37) or
hypomethylated (‘‘hyper’’, n = 130) in AIS as identified by
differential methylation analysis and CpG loci characterized by
a high variability in DNA methylation (‘‘variable’’, n = 79) as
compared to the controls.
(TIF)
Table S1 Cell strains included in this study. CAIS: complete
androgen insensitivity syndrome, female external genitalia.
(DOC)
Table S2 Loci aberrantly methylated in AIS compared to
controls. List of genes and CpG loci aberrantly methylated in AIS
as compared to normal controls. AR target genes identified using
GATHER are indicated in blue.
(XLS)
Table S3 Loci characterized by high variation in DNA
methylation patterns in AIS compared to controls. List of genes
and CpG loci characterized by a high variation in the DNA
methylation pattern in AIS as compared to normal controls
(n = 75).
(XLS)
Methods S1 Analysis of variability in the DNA methyl-
ation pattern.
(PDF)
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